BioSpace News Archive

Genedrive’s new point of care test delivers genetic results in 26 minutes, potentially saving thousands of neonates from life-long antibiotic-induced deafness.

The industry analysis report is considered a valuable source of information about the global Acromegaly Therapeutic industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market. The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic.

SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for LeukoPrint® Molecular Karyotyping Kit and is now ready to launch this test in European markets.

Zealand Pharma A/S announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

The ‘717 patent provides broad protection for Defence’s extremely versatile vaccine platform that can be incorporated into virtually any cell-based or protein subunit vaccine to enhance immunogenicity.

Viracta Therapeutics, Inc. announced that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022, at 3:00 p.m. EDT.

The aim of PharmaDrug’s DMT-analogue research program in ocular health is to develop suitable prototype medical devices capable of sustained ocular drug-delivery while also confirming efficacy, biocompatibility and stability of its candidate molecules in models of elevated IOP.

Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital exemption protocol of DT-DEC01 (Dystrophin expressing chimeric (DEC) cells), the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).

Essent Biologics™, a leading supplier of adult human-derived cell and scaffold materials, today announced it has launched a new line of primary cells: Wharton’s jelly-derived Mesenchymal Stromal Cells (hWJMSC), to its growing product portfolio.